Biogen (BIIB) – Research Analysts’ Recent Ratings Updates

Biogen (NASDAQ: BIIB) has recently received a number of price target changes and ratings updates:

• 1/10/2025 – Biogen had its price target lowered by analysts at Wells Fargo & Company from $190.00 to $165.00. They now have an “equal weight” rating on the stock.
• 1/8/2025 – Biogen had its price target lowered by analysts at Truist Financial Co. from $302.00 to $220.00. They now have a “buy” rating on the stock.
• 1/2/2025 – Biogen was downgraded by analysts at Piper Sandler from an “overweight” rating to a “neutral” rating. They now have a $138.00 price target on the stock, down previously from $315.00.
• 12/28/2024 – Biogen was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 12/20/2024 – Biogen was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 12/20/2024 – Biogen was downgraded by analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating. They now have a $164.00 price target on the stock, down previously from $230.00.
• 12/16/2024 – Biogen was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $175.00 price target on the stock.
• 12/11/2024 – Biogen was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 12/10/2024 – Biogen had its “neutral” rating reaffirmed by analysts at Bank of America Co.. They now have a $178.00 price target on the stock.
• 12/9/2024 – Biogen was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating. They now have a $180.00 price target on the stock, down previously from $250.00.
• 11/21/2024 – Biogen had its price target lowered by analysts at Mizuho from $251.00 to $207.00. They now have an “outperform” rating on the stock.
• 11/18/2024 – Biogen was downgraded by analysts at Needham & Company LLC from a “buy” rating to a “hold” rating. They now have a $270.00 price target on the stock.
• 11/15/2024 – Biogen is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.
• 11/15/2024 – Biogen had its price target raised by analysts at Robert W. Baird from $294.00 to $300.00. They now have an “outperform” rating on the stock.
• 11/14/2024 – Biogen is now covered by analysts at Citigroup Inc.. They set a “neutral” rating and a $190.00 price target on the stock.

Biogen Stock Down 1.3 %

NASDAQ:BIIB opened at $148.82 on Monday. The company has a market cap of $21.69 billion, a price-to-earnings ratio of 13.44, a price-to-earnings-growth ratio of 1.74 and a beta of -0.07. Biogen Inc. has a twelve month low of $145.07 and a twelve month high of $252.94. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. The stock has a fifty day simple moving average of $157.38 and a 200-day simple moving average of $187.29.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.77 by $0.31. The company had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.43 billion. Biogen had a net margin of 16.81% and a return on equity of 14.98%. The firm’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same quarter last year, the business posted $4.36 EPS. Analysts anticipate that Biogen Inc. will post 16.43 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. West Oak Capital LLC increased its stake in shares of Biogen by 2,000.0% during the fourth quarter. West Oak Capital LLC now owns 945 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 900 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in Biogen by 1.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,018 shares of the biotechnology company’s stock worth $767,000 after acquiring an additional 79 shares in the last quarter. Farmers Trust Co. purchased a new position in Biogen during the 4th quarter valued at about $1,965,000. Diversified Trust Co raised its holdings in shares of Biogen by 0.6% in the 4th quarter. Diversified Trust Co now owns 22,926 shares of the biotechnology company’s stock valued at $3,506,000 after purchasing an additional 143 shares in the last quarter. Finally, Nordea Investment Management AB lifted its position in shares of Biogen by 48.0% in the 4th quarter. Nordea Investment Management AB now owns 117,963 shares of the biotechnology company’s stock worth $17,901,000 after purchasing an additional 38,283 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.